The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 105.00
Bid: 102.00
Ask: 108.00
Change: 0.00 (0.00%)
Spread: 6.00 (5.882%)
Open: 105.00
High: 105.00
Low: 105.00
Prev. Close: 105.00
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Settlement of Patent Dispute

25 Mar 2010 12:30

RNS Number : 1650J
Intercede Group PLC
25 March 2010
 



25 March 2010

Intercede Group plc

("Intercede")

Settlement of Patent Litigation Between ActivIdentity and Intercede

Legal Action Terminated in California and UK

Highlights:

·; Intercede announces settlement of patent infringement disputes in the U.S. and the UK

 

·; The parties have settled the U.S. and UK litigations on mutually acceptable terms

 

London, United Kingdom 25 March 2010 - Intercede today announce that they have settled on mutually acceptable terms a lawsuit filed by ActivIdentity in the Northern District of California on 1 October 2008, and a lawsuit filed by Intercede in the UK High Court on 22 December 2009. 

The settlement entered on 23 March 2010 resolves patent litigation brought by ActivIdentity accusing Intercede's MyID products and Intercede's counterclaims alleging invalidity, violations of US antitrust law, fraud and unfair competition. This settlement includes a patent license, and the details of the settlement are confidential.

Richard Parris, Intercede's Chairman and Chief Executive, said:

 "We are pleased to end all outstanding legal disputes between Intercede and ActivIdentity and look forward to progressing our business. This settlement ensures that Intercede's worldwide partners and customers can continue to benefit from our leading MyID Identity and Credential Management System with confidence."

Intercede will take a charge to the current financial year for all of the exceptional costs associated with the legal fees relating to this case. It is not anticipated that the patent license agreement will have a material impact on Intercede's current or future earnings.

About Intercede

Intercede is the producer of the MyID® Identity and Credential Management System (IDCMS). Intercede's MyID is the only IDCMS software product that enables organizations to easily and securely manage the identities of people and their associated identity credentials within a single, integrated, workflow driven platform. This includes enabling and managing: secure registration, biometric capture, application vetting and approval through to smart card personalisation, issuance and management.

Intercede's MyID is being used around the world by large corporations, governments and banks to manage millions of identities for employees, citizens and customers. Notable deployments in the US include 10 Federal Agencies, a program with Lockheed Martin and two major US financial institutions. In Europe and the Middle East, Intercede's MyID is being deployed in support of government identity, health and corporate employee ID security projects.

For more information visit http://www.intercede.com

 

ENQUIRIES

Intercede Group plc

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

Tel. +44 (0)1455 558111

FinnCap

Clive Carver /Charles Cunningham - Corporate Finance

Joanna Weaving - Corporate Broking

Tel. +44 (0)20 7600 1658

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7337 1509

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGMGZFRKZGGZG
Date   Source Headline
10th Aug 20227:00 amRNSNotice of AGM
30th Jun 20227:00 amRNSBoard Changes
8th Jun 20227:00 amRNSFinal Results
25th May 202210:15 amRNSInvestor Presentation
12th Apr 20227:00 amRNSAppointment of CFO
6th Apr 20227:00 amRNSDirector/PDMR Shareholding
5th Apr 20227:00 amRNSTrading Update & Contract Win
30th Mar 202210:01 amRNSReceipt of $3.4m Order
2nd Feb 20227:00 amRNSContract Win
8th Dec 20213:55 pmRNSDirector/PDMR Shareholding and Issue of Equity
23rd Nov 20217:00 amRNSHalf-year Report
19th Nov 20217:00 amRNSHolding(s) in Company-Amendment
17th Nov 20217:00 amRNSInvestor Presentation
16th Nov 20217:00 amRNSHolding(s) in Company
15th Nov 20213:45 pmRNSTotal Voting Rights
11th Nov 20214:12 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSTrading Update
15th Sep 20212:09 pmRNSResult of AGM
15th Sep 20217:00 amRNSMultiple Customers choose to Upgrade MyID
20th Jul 20217:00 amRNSIntercede achieves FIDO2 certification
5th Jul 20217:00 amRNSConnect Partner Programme & Q1 Contract Wins
15th Jun 20218:26 amRNSIssue of Equity
8th Jun 20217:00 amRNSFinal Results
2nd Jun 202110:09 amRNSInvestor Presentation
10th May 20217:00 amRNSShare Incentive Plan
7th Apr 20217:00 amRNSTrading Update & Appointment of Auditor
1st Apr 202110:30 amRNSReceipt of $3.4m Order
10th Mar 20217:00 amRNSShare Incentive Plan
23rd Feb 20217:00 amRNSAmendment to LTIP
22nd Feb 20214:10 pmRNSHolding(s) in Company
16th Feb 20217:00 amRNSCLN Conversion to Equity
12th Feb 20217:00 amRNSHolding(s) in Company
8th Feb 202112:40 pmRNSHolding(s) in Company
4th Feb 20217:00 amRNSCLN Call & Issue of Equity
11th Jan 20217:00 amRNSNew Contract Win
5th Jan 202111:00 amRNSCLN Conversion to Equity
4th Jan 202110:40 amRNSHolding(s) in Company
22nd Dec 20207:00 amRNSNew Contract Win
24th Nov 20207:00 amRNSHalf-year Report
17th Nov 20207:00 amRNSContract Win: Follow-on Purchase Order
12th Nov 20207:00 amRNSInvestor Presentation
8th Oct 20207:01 amRNSIntercede join the FIDO Alliance
8th Oct 20207:00 amRNSTrading Update
16th Sep 20203:40 pmRNSResult of AGM
20th Aug 20207:05 amRNSContract Win - Initial Progress Order
5th Aug 20202:01 pmRNSHolding(s) in Company
30th Jul 20207:00 amRNSContract Win
2nd Jun 20207:00 amRNSFinal Results
12th May 20207:00 amRNSShare Incentive Plan
20th Apr 202010:02 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.